Anne Gitte Rasmussen Loft

Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Robert J Moots, Institute for Chronic Diseases and Ageing, University of Liverpool, Liverpool, UK. r.j.moots@liverpool.ac.uk
  • ,
  • Andrew J K Ostor
  • ,
  • Anne G R Loft
  • Pentti Järvinen
  • ,
  • Per Larsson
  • ,
  • Mats Ekelund
  • ,
  • Alan Reynolds
  • ,
  • Danuta Kielar
  • ,
  • Rose-Marie Lindkvist
  • ,
  • Susanne Qvitzau

OBJECTIVE: To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL).

METHODS: A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36-52 weeks with ETN 50 mg s.c. once weekly. Analysis included direct costs (transformed out-patient and in-patient care elements), indirect costs (sick leave and lost working days), efficacy and QoL.

RESULTS: Annualized direct and indirect costs decreased (55.5%, P ≤ 0.008) during ETN treatment, as did out-patient and in-patient episodes (physiotherapist/physician visits, P = 0.012). Work productivity and QoL increased.

CONCLUSION: ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS. Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42.

Original languageEnglish
JournalRheumatology
Volume51
Issue2
Pages (from-to)393-6
Number of pages4
ISSN1462-0324
DOIs
Publication statusPublished - Feb 2012

    Research areas

  • Adult, Aged, Antirheumatic Agents/administration & dosage, Efficiency, Employment, Etanercept, Female, Health Care Costs, Humans, Immunoglobulin G/administration & dosage, Male, Middle Aged, Quality of Life, Receptors, Tumor Necrosis Factor/administration & dosage, Sick Leave/statistics & numerical data, Spondylitis, Ankylosing/drug therapy, Treatment Outcome, Young Adult

See relations at Aarhus University Citationformats

ID: 131055385